Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same

Patent metadata

Field	Value
Publication number	US-10022327-B2
Application number	US-201514970998-A
Country	US
Kind code	B2
Filing date	Dec 16, 2015
Priority date	Apr 28, 2011
Publication date	Jul 17, 2018
Grant date	Jul 17, 2018

Abstract

The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

First claim

The invention claimed is:

1. A composition comprising a population of protocells comprising a mesoporous silica nanoparticle core surrounded by a lipid bilayer, wherein the protocells and the mesoporous silica nanoparticle cores in the population are monodisperse.

2. The protocell composition according to claim 1 , wherein the protocells vary no more than about 5% in diameter from a mean diameter.

3. The protocell composition according to claim 1 , wherein the protocells have a mean diameter of between about 10 nm and about 500 nm.

4. The protocell composition according to claim 1 , wherein the protocells have a mean diameter of between about 20 nm and about 200 nm.

5. The protocell composition according to claim 1 , wherein the lipid bilayer comprises cholesterol.

6. The protocell composition according to claim 1 , wherein the lipid bilayer comprises a PEG-conjugated lipid.

7. The protocell composition according to claim 1 , wherein the protocells further comprise a targeting species attached to the lipid bilayer.

8. The protocell composition according to claim 7 , wherein the targeting species is a peptide, an antibody, an antibody fragment, an aptamer, or a carbohydrate.

9. The protocell composition according to claim 1 , wherein the protocells further comprise a fusogenic peptide attached to the lipid bilayer.

10. The protocell composition according to claim 1 , wherein the protocells further comprise a cargo.

11. The protocell composition according to claim 10 , wherein the cargo is a therapeutic agent or a diagnostic agent.

12. The protocell composition according to claim 10 , wherein the cargo is a small-molecule drug, a nucleic acid, or a polypeptide.

13. The protocell composition according to claim 10 , wherein the cargo is an anti cancer agent or an antiviral agent.

14. The protocell composition according to claim 10 , wherein the cargo is DNA or RNA.

15. The protocell composition according to claim 10 , wherein the cargo is a double stranded linear DNA, a plasmid DNA, a small interfering RNA, a small hairpin RNA, or a microRNA.

16. The protocell composition according to claim 10 , wherein the cargo is an imaging agent.

17. The protocell composition according to claim 10 , wherein the cargo is a supercoiled DNA.

18. The protocell composition according to claim 10 , wherein the cargo is conjugated to a nuclear localization sequence.

19. The pro cell composition according to claim 1 , wherein the core has a multimodal pore configuration.

20. The protocell composition according to claim 1 , wherein the core comprises an organosilane.

21. The protocell composition according to claim 20 , wherein the organosilane is an amine-containing silane.

22. The protocell composition according to claim 20 , wherein the organosilane is a charged organosilane, a hydrophobic organosilane, or a reactive organosilane.

23. The protocell composition according to claim 1 , wherein the porous core has a pore volume of 0.5 to about 1.1 cubic centimeters per gram.

24. A pharmaceutical composition comprising the protocell composition according to claim 1 and a pharmaceutically acceptable excipient.

25. The pharmaceutical composition according to claim 24 in intradermal, intramuscular, intraosseous, intraperitoneal, intravenous, subcutaneous, intrathecal, topical, or transdermal dosage form.

26. A method of treating a disease in a subject comprising administering to the subject the protocell composition according to claim 10 .

27. The method according to claim 26 , wherein the disease is cancer.

Assignees

• Stc Unm
• Sandia Corp

Inventors

• Brinker C Jeffrey
• Carnes Eric C
• Ashley Carlee Erin
• Willman Cheryl L

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/18

  for HIV · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61K47/62

  the modifying agent being a protein, peptide or polyamino acid · CPC title